Humana Inc. (HUM) climbs after CMS released 2027 Medicare Advantage Star Ratings, lifting its largest contract back to 4 stars from 3.5. The upgrade improves the outlook for bonus payments, rebates, and enrollment competitiveness, while recent earnings strength adds support to the move.
Humana Inc. (HUM) climbed sharply after CMS published its 2027 Medicare Advantage Star Ratings, with the company’s largest contract recovering to 4 stars from 3.5. That improvement should support bonus payments, rebates, and plan competitiveness, giving Humana a stronger earnings and enrollment outlook even as its valuation remains elevated.
Humana Inc. (HUM) climbs 13.10% to $437.85 in after-hours trading after CMS published its 2027 Medicare Advantage Star Ratings. The move matters because Humana’s largest Medicare Advantage contract recovered to 4 stars from 3.5 stars, improving the outlook for bonus payments, rebates, and plan competitiveness; regular-session trading will confirm whether the jump holds.
Key Takeaways
HUM rose to $437.85 after hours, a $50.73 gain from the $387.12 regular-session close.
The main catalyst was CMS’s 2027 Star Ratings release and the recovery of Humana’s largest contract to 4 stars.
Humana reported Q2 EPS of $7.61, beating the $6.22 estimate by 22.3%, adding financial support to the rally.
The listed P/E of 37.48 leaves less room for disappointment, so investors should separate the ratings improvement from the stock’s valuation.
What Is Behind Humana’s After-Hours Rally Today
The specific catalyst is the published by the Centers for Medicare & Medicaid Services on October 8, 2026. Humana’s largest Medicare Advantage contract moved from 3.5 stars to 4 stars. That was a meaningful reversal for a company whose earnings depend heavily on Medicare Advantage economics.
CMS Star Ratings affect quality bonus payments and rebate levels. They also influence enrollment appeal, marketing strength, and member retention. Therefore, a higher rating can improve the economics of a large contract while supporting Humana’s position during the 2027 Open Enrollment period, which begins October 15, 2026.
The market reaction reinforces the stock-specific nature of the news. Humana shares gained 16.5% intraday, while Alignment Healthcare fell more than 20% after the ratings changes. That split suggests investors rewarded Humana’s contract improvement rather than simply buying the entire managed-care group.
The rally also followed a volatile regular session. HUM traded between $377.06 and $453.93 on 2.65 million shares before the after-hours rebound. Such a wide range shows that traders were reassessing the value of the ratings update in real time, with profit-taking adding noise to an otherwise positive catalyst.
How Humana’s Earnings and Valuation Frame the Move
Humana entered this event with improving earnings momentum. The company reported Q2 EPS of $7.61 on July 29, 2026, compared with a $6.22 estimate. That 22.3% beat was Humana’s sixth beat in seven reported quarters, giving investors a concrete earnings base for a ratings-driven revaluation.
The valuation, however, is no longer a simple distressed-stock story. The listed EPS is $10.58, the P/E is 37.48, the market capitalization is $46.49B, and the dividend yield is 0.88%. Those figures show that the market already assigns meaningful value to a recovery in earnings. The improved Star Rating strengthens that case, but it does not erase execution risk.
The practical investor lesson is straightforward: the rating improvement supports future earnings power, while the valuation demands evidence that the improvement can last. A 4-star contract can lift bonus revenue and plan appeal, but medical costs still determine how much of that benefit reaches profit.
Humana’s Medicare Advantage Position and Competitive Advantage
Humana operates through Insurance and CenterWell. Insurance remains the core earnings engine, while CenterWell provides primary care and pharmacy-related services for older adults. That structure gives Humana a wider consumer healthcare platform than a standalone insurance business.
Scale remains a major advantage. Humana competes with UnitedHealth, CVS’s Aetna, and Elevance in Medicare Advantage. Its plans often include dental, vision, and hearing benefits that Original Medicare does not provide. Those extras help attract members, but they also make profitability more sensitive to medical utilization and benefit costs.
That balance explains why the Star Rating matters so much. Humana has faced pressure from rising medical utilization, membership mix changes, and weaker ratings on some contracts. The move back to 4 stars addresses one part of that pressure and gives the company a stronger platform for enrollment and retention.
Still, a quality rating is not a complete competitive moat. Rivals can adjust benefits, prices, and care programs quickly. Humana’s CenterWell strategy could support lower medical costs over time, but the stock’s long-term case requires that operating benefit to work alongside stronger ratings.
HUM Stock Outlook After the 2027 Star Ratings Surprise
The near-term outlook improved because the 4-star recovery directly affects the business cycle ahead. CMS ratings influence 2027 enrollment and 2028 quality bonus payments. That timing gives Humana a measurable operating benefit rather than a headline with no financial connection.
However, investors should treat the after-hours quote as a repricing signal, not a finished investment thesis. HUM’s $437.85 print sits above the listed 52-week high of $428.88. The regular session therefore matters: sustained trading above that prior high would show stronger acceptance, while a sharp retreat would signal that traders view the initial jump as excessive.
The disciplined approach is to connect price action with fundamentals. The Star Rating provides the catalyst, Q2’s 22.3% EPS beat provides earnings support, and the 37.48 P/E sets a demanding valuation bar. Together, those facts support a constructive outlook, but rising medical costs and benefit pressure remain the counterweight.
Humana’s move is best understood as a Medicare Advantage quality reset. The 3.5-to-4-star recovery improves the company’s payment and enrollment prospects, while recent earnings show that the business already has profit momentum. Yet after a 13.10% extended-hours jump, investors need the regular session to prove that the market accepts the new valuation.
HUM stock is up because CMS released its 2027 Medicare Advantage Star Ratings, and Humana’s largest contract improved from 3.5 stars to 4 stars. That raises the potential for better bonus payments, rebates, and enrollment appeal.
+Should I buy HUM stock now?
The ratings improvement is a positive catalyst, but the stock already trades at a demanding valuation, so this is not a low-risk entry. Investors should weigh the stronger Medicare Advantage outlook against execution risk and elevated expectations.
+What does the 4-star rating mean for Humana?
A 4-star rating can improve Humana’s economics through higher quality bonus payments and better rebate levels. It can also strengthen the company’s competitiveness during open enrollment by making its plans more attractive to members.
+Will HUM’s after-hours gain hold in regular trading?
It could, but the regular session will determine whether buyers accept the new valuation. If the stock holds above its prior high, that would signal strong confidence in the ratings-driven rally.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on HUM?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
